2 Information about sofosbuvir–velpatasvir–voxilaprevir

Information about sofosbuvir–velpatasvir–voxilaprevir

Marketing authorisation indication

Sofosbuvir–velpatasvir–voxilaprevir (Vosevi, Gilead Sciences) has a marketing authorisation in the UK for 'the treatment of chronic hepatitis C virus infection in adults'.

This includes genotypes 1–6, with or without compensated cirrhosis, and includes people who have had previous treatment with direct-acting antivirals.

Dosage in the marketing authorisation

The recommended dose is 1 tablet taken orally once daily. Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir.

Treatment duration is 8 or 12 weeks depending on cirrhosis status and whether the person has had previous treatment with direct-acting antivirals. Please see the summary of product characteristics for more details.


Sofosbuvir–velpatasvir–voxilaprevir costs £14,942.33 per 28‑day pack. The total costs are £29,884.66 for an 8-week course and £44,826.99 for a 12-week course (company submission).

The company agreed a nationally available price reduction for sofosbuvir–velpatasvir–voxilaprevir with the Commercial Medicines Unit. The contract prices agreed through the framework are commercial in confidence.

  • National Institute for Health and Care Excellence (NICE)